Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals

DOI record: { "DOI": "10.1038/s41598-025-02240-3", "ISSN": [ "2045-2322" ], "URL": "http://dx.doi.org/10.1038/s41598-025-02240-3", "alternative-id": [ "2240" ], "article-number": "17578", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "27 January 2025" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "12 May 2025" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "21 May 2025" }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "The authors declare no competing interests." } ], "author": [ { "ORCID": "https://orcid.org/0009-0000-6779-7788", "affiliation": [], "authenticated-orcid": false, "family": "Dluzynski", "given": "Daniela", "sequence": "first" }, { "affiliation": [], "family": "Ssentongo", "given": "Paddy", "sequence": "additional" }, { "affiliation": [], "family": "Hale", "given": "Cory M.", "sequence": "additional" }, { "affiliation": [], "family": "Shaheen", "given": "Shareef K.", "sequence": "additional" }, { "affiliation": [], "family": "Maglakelidze", "given": "Natella", "sequence": "additional" }, { "affiliation": [], "family": "Sivik", "given": "Jeffrey M.", "sequence": "additional" }, { "affiliation": [], "family": "Henao", "given": "Maria Paula", "sequence": "additional" }, { "affiliation": [], "family": "Chinchilli", "given": "Vernon M.", "sequence": "additional" }, { "affiliation": [], "family": "Paules", "given": "Catharine I.", "sequence": "additional" } ], "container-title": "Scientific Reports", "container-title-short": "Sci Rep", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2025, 5, 21 ] ], "date-time": "2025-05-21T04:48:25Z", "timestamp": 1747802905000 }, "deposited": { "date-parts": [ [ 2025, 5, 21 ] ], "date-time": "2025-05-21T04:48:29Z", "timestamp": 1747802909000 }, "indexed": { "date-parts": [ [ 2025, 5, 22 ] ], "date-time": "2025-05-22T04:07:07Z", "timestamp": 1747886827514, "version": "3.41.0" }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2025, 5, 21 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2025, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 5, 21 ] ], "date-time": "2025-05-21T00:00:00Z", "timestamp": 1747785600000 } }, { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 5, 21 ] ], "date-time": "2025-05-21T00:00:00Z", "timestamp": 1747785600000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41598-025-02240-3.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-025-02240-3", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-025-02240-3.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2025, 5, 21 ] ] }, "published-online": { "date-parts": [ [ 2025, 5, 21 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "2240_CR1", "unstructured": "Data from: Provisional COVID-19 Deaths by Sex and Age. (Centers for Disease Control and Prevention, 2023)." }, { "key": "2240_CR2", "unstructured": "WHO Coronavirus (COVID-19) Dashboard. World Health Organization. Accessed September 2nd, 2023. https://covid19.who.int/ (2023)" }, { "DOI": "10.1038/s41577-021-00592-1", "author": "JS Tregoning", "doi-asserted-by": "publisher", "first-page": "626", "issue": "10", "journal-title": "Nat. Rev. Immunol.", "key": "2240_CR3", "unstructured": "Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21(10), 626–636. https://doi.org/10.1038/s41577-021-00592-1 (2021).", "volume": "21", "year": "2021" }, { "DOI": "10.15585/mmwr.mm7127a3", "author": "JRC Singson", "doi-asserted-by": "publisher", "first-page": "878", "issue": "27", "journal-title": "MMWR Morb. Mortal. Wkly Rep.", "key": "2240_CR4", "unstructured": "Singson, J. R. C. et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19-COVID-NET, 10 States, March 2020–February 2022. MMWR Morb. Mortal. Wkly Rep. 71(27), 878–884. https://doi.org/10.15585/mmwr.mm7127a3 (2022).", "volume": "71", "year": "2022" }, { "DOI": "10.1001/jama.2016.16477", "author": "R Harpaz", "doi-asserted-by": "publisher", "first-page": "2547", "issue": "23", "journal-title": "JAMA", "key": "2240_CR5", "unstructured": "Harpaz, R., Dahl, R. M. & Dooling, K. L. Prevalence of Immunosuppression among US Adults, 2013. JAMA 316(23), 2547–2548. https://doi.org/10.1001/jama.2016.16477 (2016).", "volume": "316", "year": "2016" }, { "DOI": "10.1016/S2214-109X(21)00593-3", "author": "EPK Parker", "doi-asserted-by": "publisher", "first-page": "e326", "issue": "3", "journal-title": "Lancet Glob. Health", "key": "2240_CR6", "unstructured": "Parker, E. P. K. et al. Response to additional COVID-19 vaccine doses in people who are immunocompromised: A rapid review. Lancet Glob. Health 10(3), e326–e328. https://doi.org/10.1016/S2214-109X(21)00593-3 (2022).", "volume": "10", "year": "2022" }, { "DOI": "10.1056/NEJMra2206573", "author": "DH Barouch", "doi-asserted-by": "publisher", "first-page": "1011", "issue": "11", "journal-title": "N. Engl. J. Med.", "key": "2240_CR7", "unstructured": "Barouch, D. H. Covid-19 vaccines—Immunity, variants, boosters. N. Engl. J. Med. 387(11), 1011–1020. https://doi.org/10.1056/NEJMra2206573 (2022).", "volume": "387", "year": "2022" }, { "DOI": "10.1136/bmj-2021-068632", "author": "ARYB Lee", "doi-asserted-by": "publisher", "first-page": "e068632", "journal-title": "BMJ", "key": "2240_CR8", "unstructured": "Lee, A. R. Y. B. et al. Efficacy of covid-19 vaccines in immunocompromised patients: Systematic review and meta-analysis. BMJ 376, e068632. https://doi.org/10.1136/bmj-2021-068632 (2022).", "volume": "376", "year": "2022" }, { "DOI": "10.1038/s41591-023-02414-4", "author": "E Barnes", "doi-asserted-by": "publisher", "first-page": "1760", "issue": "7", "journal-title": "Nat. Med.", "key": "2240_CR9", "unstructured": "Barnes, E. et al. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nat. Med. 29(7), 1760–1774. https://doi.org/10.1038/s41591-023-02414-4 (2023).", "volume": "29", "year": "2023" }, { "key": "2240_CR10", "unstructured": "EVUSHELD: Emergency Use Authorization (EAU)—Full fact sheet for healthcare providers. US Food and Drug Administration. Accessed 06 May 2022, https://www.fda.gov/media/154701/download" }, { "key": "2240_CR11", "unstructured": "FDA announces Evusheld is not currently authorized for emergency use in the U.S. (U.S. Food and Drug Administration, 2023)." }, { "DOI": "10.1056/NEJMoa2116620", "author": "MJ Levin", "doi-asserted-by": "publisher", "first-page": "2188", "issue": "23", "journal-title": "N. Engl. J. Med.", "key": "2240_CR12", "unstructured": "Levin, M. J. et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of covid-19. N. Engl. J. Med. 386(23), 2188–2200. https://doi.org/10.1056/NEJMoa2116620 (2022).", "volume": "386", "year": "2022" }, { "DOI": "10.1038/s41591-022-01792-5", "author": "T Bruel", "doi-asserted-by": "publisher", "first-page": "1297", "issue": "6", "journal-title": "Nat. Med.", "key": "2240_CR13", "unstructured": "Bruel, T. et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. 28(6), 1297–1302. https://doi.org/10.1038/s41591-022-01792-5 (2022).", "volume": "28", "year": "2022" }, { "DOI": "10.1038/s41598-022-16964-z", "author": "F Touret", "doi-asserted-by": "publisher", "first-page": "12609", "issue": "1", "journal-title": "Sci. Rep.", "key": "2240_CR14", "unstructured": "Touret, F. et al. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5. Sci. Rep. 12(1), 12609. https://doi.org/10.1038/s41598-022-16964-z (2022).", "volume": "12", "year": "2022" }, { "DOI": "10.1002/rmv.2483", "author": "BA Randi", "doi-asserted-by": "publisher", "issue": "6", "journal-title": "Rev. Med. Virol.", "key": "2240_CR15", "unstructured": "Randi, B. A. et al. COVID-19 in hematopoietic stem-cell transplant recipients: A systematic review and meta-analysis of clinical characteristics and outcomes. Rev. Med. Virol. 33(6), e2483. https://doi.org/10.1002/rmv.2483 (2023).", "volume": "33", "year": "2023" }, { "DOI": "10.1186/s13045-022-01387-0", "author": "L Jondreville", "doi-asserted-by": "publisher", "first-page": "169", "issue": "1", "journal-title": "J. Hematol. Oncol.", "key": "2240_CR16", "unstructured": "Jondreville, L. et al. Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: A multicentric retrospective study of SFGM-TC. J. Hematol. Oncol. 15(1), 169. https://doi.org/10.1186/s13045-022-01387-0 (2022).", "volume": "15", "year": "2022" }, { "DOI": "10.1111/bjh.17260", "author": "A Xhaard", "doi-asserted-by": "publisher", "first-page": "e121", "issue": "5", "journal-title": "Br. J. Haematol.", "key": "2240_CR17", "unstructured": "Xhaard, A. et al. Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: A Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM-TC) multicentre cohort study. Br. J. Haematol. 192(5), e121–e124. https://doi.org/10.1111/bjh.17260 (2021).", "volume": "192", "year": "2021" }, { "DOI": "10.1016/j.retram.2023.103402", "author": "E Xue", "doi-asserted-by": "publisher", "first-page": "103402", "issue": "3", "journal-title": "Curr. Res. Transl. Med.", "key": "2240_CR18", "unstructured": "Xue, E. et al. Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: A single center experience. Curr. Res. Transl. Med. 71(3), 103402. https://doi.org/10.1016/j.retram.2023.103402 (2023).", "volume": "71", "year": "2023" }, { "key": "2240_CR19", "unstructured": "GISAID. SARS-CoV-2 sequences by variant, Dec 18, 2023. Our World in Data. Accessed January 6, 2024. https://gisaid.org/" }, { "DOI": "10.1038/s41591-022-02162-x", "author": "C Kurhade", "doi-asserted-by": "publisher", "first-page": "344", "issue": "2", "journal-title": "Nat. Med.", "key": "2240_CR20", "unstructured": "Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.275.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med. 29(2), 344–347. https://doi.org/10.1038/s41591-022-02162-x (2023).", "volume": "29", "year": "2023" }, { "DOI": "10.1021/acs.jcim.2c01352", "author": "J Chen", "doi-asserted-by": "publisher", "first-page": "335", "issue": "1", "journal-title": "J. Chem. Inf. Model.", "key": "2240_CR21", "unstructured": "Chen, J. et al. Emerging dominant SARS-CoV-2 variants. J. Chem. Inf. Model. 63(1), 335–342. https://doi.org/10.1021/acs.jcim.2c01352 (2023).", "volume": "63", "year": "2023" }, { "DOI": "10.1128/mbio.01024-23", "author": "Y Young-Xu", "doi-asserted-by": "publisher", "first-page": "e0102423", "issue": "4", "journal-title": "MBio", "key": "2240_CR22", "unstructured": "Young-Xu, Y. et al. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: Retrospective analysis of National Veterans Health Administration electronic data. MBio 14(4), e0102423. https://doi.org/10.1128/mbio.01024-23 (2023).", "volume": "14", "year": "2023" }, { "DOI": "10.1093/cid/ciac855", "author": "R Najjar-Debbiny", "doi-asserted-by": "publisher", "first-page": "1067", "issue": "6", "journal-title": "Clin. Infect. Dis.", "key": "2240_CR23", "unstructured": "Najjar-Debbiny, R., Gronich, N., Weber, G., Stein, N. & Saliba, W. Effectiveness of evusheld in immunocompromised patients: Propensity score-matched analysis. Clin. Infect. Dis. 76(6), 1067–1073. https://doi.org/10.1093/cid/ciac855 (2023).", "volume": "76", "year": "2023" }, { "author": "A Tong", "first-page": "302", "issue": "6", "journal-title": "J. Hematol. Oncol. Pharm.", "key": "2240_CR24", "unstructured": "Tong, A. et al. Real-world efficacy and safety of tixagevimab plus cilgavimab in patients with cancer. J. Hematol. Oncol. Pharm. 13(6), 302–312 (2023).", "volume": "13", "year": "2023" }, { "DOI": "10.1097/TXD.0000000000001485", "author": "D Sindu", "doi-asserted-by": "publisher", "issue": "6", "journal-title": "Transplant Direct.", "key": "2240_CR25", "unstructured": "Sindu, D. et al. Pre-exposure prophylaxis with tixagevimab–cilgavimab did not reduce severity of COVID-19 in lung transplant recipients with breakthrough infection. Transplant Direct. 9(6), e1485. https://doi.org/10.1097/TXD.0000000000001485 (2023).", "volume": "9", "year": "2023" }, { "DOI": "10.14740/jh1062", "author": "AJ Ocon", "doi-asserted-by": "publisher", "first-page": "210", "issue": "6", "journal-title": "J. Hematol.", "key": "2240_CR26", "unstructured": "Ocon, A. J. et al. Real-world effectiveness of tixagevimab and cilgavimab (evusheld) in patients with hematological malignancies. J. Hematol. 11(6), 210–215. https://doi.org/10.14740/jh1062 (2022).", "volume": "11", "year": "2022" }, { "DOI": "10.1097/RHU.0000000000001907", "author": "AJ Ocon", "doi-asserted-by": "publisher", "first-page": "109", "issue": "2", "journal-title": "J. Clin. Rheumatol.", "key": "2240_CR27", "unstructured": "Ocon, A. J. & Mustafa, S. S. Real-world experience of tixagevimab and cilgavimab (evusheld) in rheumatologic patients on rituximab. J. Clin. Rheumatol. 29(2), 109–111. https://doi.org/10.1097/RHU.0000000000001907 (2023).", "volume": "29", "year": "2023" }, { "DOI": "10.1016/j.xcrm.2022.100850", "author": "T Bruel", "doi-asserted-by": "publisher", "first-page": "100850", "issue": "12", "journal-title": "Cell Rep. Med.", "key": "2240_CR28", "unstructured": "Bruel, T. et al. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies. Cell Rep. Med. 3(12), 100850. https://doi.org/10.1016/j.xcrm.2022.100850 (2022).", "volume": "3", "year": "2022" }, { "DOI": "10.1101/2022.11.17.516888", "doi-asserted-by": "publisher", "key": "2240_CR29", "unstructured": "Planas, D., Bruel, T., Staropoli, I, et al. Resistance of Omicron subvariants BA2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies. bioRxiv. https://doi.org/10.1101/2022.11.17.516888 (2022)." }, { "DOI": "10.1002/jmv.28932", "author": "Q Zhao", "doi-asserted-by": "publisher", "first-page": "e28932", "issue": "7", "journal-title": "J. Med. Virol.", "key": "2240_CR30", "unstructured": "Zhao, Q. et al. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld. J. Med. Virol. 95(7), e28932. https://doi.org/10.1002/jmv.28932 (2023).", "volume": "95", "year": "2023" }, { "DOI": "10.1016/j.jinf.2022.10.006", "author": "X de Lamballerie", "doi-asserted-by": "publisher", "first-page": "66", "issue": "1", "journal-title": "J. Infect.", "key": "2240_CR31", "unstructured": "de Lamballerie, X. et al. Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation. J. Infect. 86(1), 66–117. https://doi.org/10.1016/j.jinf.2022.10.006 (2023).", "volume": "86", "year": "2023" }, { "DOI": "10.3324/haematol.2023.283015", "author": "JC Laracy", "doi-asserted-by": "publisher", "first-page": "3058", "issue": "11", "journal-title": "Haematologica", "key": "2240_CR32", "unstructured": "Laracy, J. C. et al. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab–cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients. Haematologica 108(11), 3058–3067. https://doi.org/10.3324/haematol.2023.283015 (2023).", "volume": "108", "year": "2023" }, { "DOI": "10.1001/jama.2020.10245", "author": "M Marovich", "doi-asserted-by": "publisher", "first-page": "131", "issue": "2", "journal-title": "JAMA", "key": "2240_CR33", "unstructured": "Marovich, M., Mascola, J. R. & Cohen, M. S. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA 324(2), 131–132. https://doi.org/10.1001/jama.2020.10245 (2020).", "volume": "324", "year": "2020" }, { "key": "2240_CR34", "unstructured": "AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023. AstraZeneca; 2023. Accessed January 6, 2023. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-reinforces-commitment-to-protecting-the-most-vulnerable-from-serious-infectious-diseases-at-idweek-2023.html" }, { "DOI": "10.1056/NEJMoa2110275", "author": "LL Hammitt", "doi-asserted-by": "publisher", "first-page": "837", "issue": "9", "journal-title": "N. Engl. J. Med.", "key": "2240_CR35", "unstructured": "Hammitt, L. L. et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N. Engl. J. Med. 386(9), 837–846. https://doi.org/10.1056/NEJMoa2110275 (2022).", "volume": "386", "year": "2022" }, { "key": "2240_CR36", "unstructured": "Administration USFaD. Fact Sheet for Healthcare Providers: Emergency Use Authorization of Pemgarda (Pemivibart) [Fact Sheet] (2024)." } ], "reference-count": 36, "references-count": 36, "relation": {}, "resource": { "primary": { "URL": "https://www.nature.com/articles/s41598-025-02240-3" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals", "type": "journal-article", "update-policy": "https://doi.org/10.1007/springer_crossmark_policy", "volume": "15" }